Objetivo: Valoración clínica y de la calidad de vida del paciente insomne. Tipo de estudio: Descriptivo transversal. Emplazamiento: Atención Primaria de Toledo. Población: Pacientes diagnosticados de insomnio antes de enero de 2008. Mediciones: Revisión historia clínica: registro de actividades diagnóstico-terapéuticas y entrevista telefónica para realizar historia del sueño y cuestionario EQ-5D. Resultados: N = 94. Edad media 60,3 ± 14,3 años. 79,8% mujeres. El 73,4% (IC 95%: 62,0-80,0) presentaba eficiencia del sueño ≤ 90%. El 69,1% (IC 95%: 58,6-78,0) refería dormir mal. Repercusiones: 76,8% dice levantarse cansado, interfiere en la actividad del 70,6%; al 63,2% le ocasiona distracciones y al 39,7% somnolencia diurna. El 58,1% sufre insomnio de conciliación, 25,8% de mantenimiento, 8,6% despertar precoz. El 27,8% de pacientes recibió recomendaciones de higiene del sueño. Principios más prescritos: lorazepam (47,2%), lormetazepam (23,6%) y zolpidem (19,1%). Mediana de duración del tratamiento: 32 semanas (RI 58). Actualmente no tomaba tratamiento el 24,7%. De ellos, decía dormir bien el 21,7%. Consideraba su salud buena/muy buena el 17,2% de los tratados y el 26,1% de los no tratados. Presentaban peores puntuaciones en EVA del EQ-5D los de mayor edad (r = -0,33; p = 0,001), los que referían dormir mal (55,8 vs 53,2; t = 0,52; p > 0,05), aquellos con despertar precoz (F = 3,51; p = 0,01) y los tratados farmacológicamente (51,5 vs 61,5; t = 1,93; p = 0,06). Conclusiones: La mayoría de los pacientes insomnes continúa durmiendo mal y presenta mala eficiencia del sueño aún con tratamiento farmacológico. La principal repercusión es el cansancio, que interfiere en su actividad habitual. El insomnio repercute negativamente en la calidad de vida.

Objective: Clinical assessment and quality of life of the insomniac patient. Design: cross-sectional study. Setting: Primary Health Care. Toledo (Spain). Participants: Patients diagnosed with insomnia before January 2009. Measurements: Medical history review: record of diagnostic and therapeutic activities. Telephone interview: sleep history and EQ-5D questionnaire Results: N = 94. Average age 60.3 ± 14.3 years, 79.8% are women. 73.4% (95%CI 62.0-80.0%) had less than 90% sleep efficiency and 69.1% said they sleep badly. Impact: 76.8% get up feeling tired; in 70.6% insomnia interferes with their activities, in 63.2% it causes distractions and in 39.7% daytime sleepiness. 58.1% have conciliation insomnia, 25.8% have maintenance insomnia, and 8.6% early awakening. 27.8% of patients received advice on sleep hygiene. The most commonly prescribed drugs were lorazepam (47.2%), lormetazepam (23.6%) and zolpidem (19.1%). Median duration of treatment was 32 weeks (RI 58). Currently 24.7% are not taking any treatment, 21.7% of whom said they sleep well. 17.2% of those who were treated and 26.1% of those who were not considered they were in good or very good health. Older patients (r= -0.33; p = 0.001), those who said they sleep badly (55.8 vs 53.2; t = 0, 52; p > 0.05), those with early awakening (F = 3.51; p = 0.01) and those on pharmacotherapy (51.5 vs 61.5; t = 1.93 p = 0.06) had the worst scores in the EQ5D. Conclusions: Most patients with insomnia continue to sleep badly and have poor sleep efficiency, even with pharmacological treatment. The main impact is tiredness, which interferes with their normal activities. Insomnia has a negative effect on the quality of life.